Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate hepatitis by 2030.

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company ...

In a pair of articles published in Lancet Gastroenterology & Hepatology, scientists lay out the case for why we should expand ...

A study just published on Eurosurveillance has found evidence of substantial lifetime exposure to hepatitis B and C viruses in Ukraine in a 2021 nationwide, representative sample of the population, ...

Discover a study comparing HBV- and alcohol-related ACLF, highlighting distinct clinical profiles and the need for aetiology-specific treatment strategies.

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...

TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich, has entered its first clinical trial in patients. Following a successful phase 1a ...

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B ...

ABI-6250: An oral viral entry inhibitor candidate for hepatitis D virus (HDV) infection The late-breaker poster presentation titled “ Preclinical profiling of ABI-6250, a first-in-class oral ...

Additionally, in vitro data presented for ABI-4334 provide further insights into the potential for next-generation capsid assembly modulators to impact markers of chronic HBV infection.